SDH Mutations Establish a Hypermethylator Phenotype in Paraganglioma

Cancer Cell

Volumn 23, Issue 6, 2013, Pages 739-752

  Letouzé, Eric ^a   Martinelli, Cosimo ^b,c   Loriot, Céline ^b,c   Burnichon, Nelly ^b,c,d   Abermil, Nasséra ^c,d   Ottolenghi, Chris ^c,e,f   Janin, Maxime ^e,f   Menara, Mélanie ^b,c   Nguyen, AnThach ^b,c   Benit, Paule ^g   Buffet, Alexandre ^b,c   Marcaillou, Charles ^h   Bertherat, JérÔme ^c,i,j,k   Amar, Laurence ^c,d,k   Rustin, Pierre ^g   DeReyniès, Aurélien ^a   Gimenez Roqueplo, Anne Paule ^b,c,d,k   Favier, Judith ^b,c  

^a Ligue Nationale Contre le Cancer   (France)

^b PARIS CARDIOVASCULAR RESEARCH CENTER   (France)

^c UNIVERSITÉ PARIS DESCARTES   (France)

^d HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^e HÔPITAL NECKER ENFANTS MALADES   (France)

^f INSERM   (France)

^g HÔPITAL ROBERT DEBRÉ   (France)

^h IntegraGen   (France)

ⁱ CentredeRéference Maladies Rares de la Surrenale ^*  (France)

^j INSTITUT COCHIN   (France)

^k INSTITUT NATIONAL DU CANCER   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; DNA; DNA METHYLTRANSFERASE; HISTONE;

ADOLESCENT; ADULT; AGED; ARTICLE; CHILD; CLINICAL FEATURE; DNA METHYLATION; EPIGENETICS; FEMALE; FH GENE; GENE; GENE MUTATION; GENE SILENCING; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PARAGANGLIOMA; PHENOTYPE; PHEOCHROMOCYTOMA; PRIORITY JOURNAL; SCHOOL CHILD; SUCCINATE DEHYDROGENASE GENE;

EID: 84878969599     PISSN: 15356108     EISSN: 18783686     Source Type: Journal    
DOI: 10.1016/j.ccr.2013.04.018     Document Type: Article

References (57)

1. Amar L., Bertherat J., Baudin E., Ajzenberg C., Bressac-de Paillerets B., Chabre O., Chamontin B., Delemer B., Giraud S., Murat A., et al. Genetic testing in pheochromocytoma or functional paraganglioma. J. Clin. Oncol. 2005, 23:8812-8818.
2. Amar L., Baudin E., Burnichon N., Peyrard S., Silvera S., Bertherat J., Bertagna X., Schlumberger M., Jeunemaitre X., Gimenez-Roqueplo A.P., Plouin P.F. Succinate dehydrogenase B gene mutations predict survival in patients with malignant pheochromocytomas or paragangliomas. J. Clin. Endocrinol. Metab. 2007, 92:3822-3828.
3. Baysal B.E., Ferrell R.E., Willett-Brozick J.E., Lawrence E.C., Myssiorek D., Bosch A., van der Mey A., Taschner P.E., Rubinstein W.S., Myers E.N., et al. Mutations in SDHD, a mitochondrial complex II gene, in hereditary paraganglioma. Science 2000, 287:848-851.
4. Bibikova M., Le J., Barnes B., Saedinia-Melnyk S., Zhou L., Shen R., Gunderson K.L. Genome-wide DNA methylation profiling using Infinium® assay. Epigenomics 2009, 1:177-200.
5. Brière J.J., Favier J., Bénit P., El Ghouzzi V., Lorenzato A., Rabier D., Di Renzo M.F., Gimenez-Roqueplo A.P., Rustin P. Mitochondrial succinate is instrumental for HIF1alpha nuclear translocation in SDHA-mutant fibroblasts under normoxic conditions. Hum. Mol. Genet. 2005, 14:3263-3269.
6. Burnichon N., Vescovo L., Amar L., Libé R., de Reynies A., Venisse A., Jouanno E., Laurendeau I., Parfait B., Bertherat J., et al. Integrative genomic analysis reveals somatic mutations in pheochromocytoma and paraganglioma. Hum. Mol. Genet. 2011, 20:3974-3985.
7. Burnichon N., Buffet A., Parfait B., Letouzé E., Laurendeau I., Loriot C., Pasmant E., Abermil N., Valeyrie-Allanore L., Bertherat J., et al. Somatic NF1 inactivation is a frequent event in sporadic pheochromocytoma. Hum. Mol. Genet. 2012, 21:5397-5405.
8. Burnichon N., Cascón A., Schiavi F., Morales N.P., Comino-Méndez I., Abermil N., Inglada-Pérez L., de Cubas A.A., Amar L., Barontini M., et al. MAX mutations cause hereditary and sporadic pheochromocytoma and paraganglioma. Clin. Cancer Res. 2012, 18:2828-2837.
9. Cedar H., Bergman Y. Linking DNA methylation and histone modification: patterns and paradigms. Nat. Rev. Genet. 2009, 10:295-304.
10. Dahia P.L., Ross K.N., Wright M.E., Hayashida C.Y., Santagata S., Barontini M., Kung A.L., Sanso G., Powers J.F., Tischler A.S., et al. A HIF1alpha regulatory loop links hypoxia and mitochondrial signals in pheochromocytomas. PLoS Genet. 2005, 1:72-80.
11. deS Senanayake P., Denker J., Bravo E.L., Graham R.M. Production, characterization, and expression of neuropeptide Y by human pheochromocytoma. J. Clin. Invest. 1995, 96:2503-2509.
12. Eisenhofer G., Walther M.M., Huynh T.T., Li S.T., Bornstein S.R., Vortmeyer A., Mannelli M., Goldstein D.S., Linehan W.M., Lenders J.W., Pacak K. Pheochromocytomas in von Hippel-Lindau syndrome and multiple endocrine neoplasia type 2 display distinct biochemical and clinical phenotypes. J. Clin. Endocrinol. Metab. 2001, 86:1999-2008.
13. Eisenhofer G., Pacak K., Huynh T.T., Qin N., Bratslavsky G., Linehan W.M., Mannelli M., Friberg P., Grebe S.K., Timmers H.J., et al. Catecholamine metabolomic and secretory phenotypes in phaeochromocytoma. Endocr. Relat. Cancer 2011, 18:97-111.
14. Eppig J.T., Blake J.A., Bult C.J., Kadin J.A., Richardson J.E. The Mouse Genome Database (MGD): comprehensive resource for genetics and genomics of the laboratory mouse. Nucleic Acids Res. 2012, 40(Database issue):D881-D886. Mouse Genome Database Group.
15. Esteller M., Guo M., Moreno V., Peinado M.A., Capella G., Galm O., Baylin S.B., Herman J.G. Hypermethylation-associated inactivation of the cellular retinol-binding-protein 1 gene in human cancer. Cancer Res. 2002, 62:5902-5905.
16. Farias E.F., Ong D.E., Ghyselinck N.B., Nakajo S., Kuppumbatti Y.S., Mira y Lopez R. Cellular retinol-binding protein I, a regulator of breast epithelial retinoic acid receptor activity, cell differentiation, and tumorigenicity. J. Natl. Cancer Inst. 2005, 97:21-29.
17. Favier J., Brière J.J., Burnichon N., Rivière J., Vescovo L., Benit P., Giscos-Douriez I., De Reyniès A., Bertherat J., Badoual C., et al. The Warburg effect is genetically determined in inherited pheochromocytomas. PLoS ONE 2009, 4:e7094.
18. Favier J., Buffet A., Gimenez-Roqueplo A.P. HIF2A mutations in paraganglioma with polycythemia. N.Engl. J. Med. 2012, 367:2161. author reply 2161-2162.
19. Feinberg A.P., Vogelstein B. Hypomethylation distinguishes genes of some human cancers from their normal counterparts. Nature 1983, 301:89-92.
20. Geli J., Kiss N., Karimi M., Lee J.J., Bäckdahl M., Ekström T.J., Larsson C. Global and regional CpG methylation in pheochromocytomas and abdominal paragangliomas: association to malignant behavior. Clin. Cancer Res. 2008, 14:2551-2559.
21. Gimenez-Roqueplo A.P., Dahia P.L., Robledo M. An update on the genetics of paraganglioma, pheochromocytoma, and associated hereditary syndromes. Horm. Metab. Res. 2012, 44:328-333.
22. Gimenez-Roqueplo A.P., Favier J., Rustin P., Mourad J.J., Plouin P.F., Corvol P., Rötig A., Jeunemaitre X. The R22X mutation of the SDHD gene in hereditary paraganglioma abolishes the enzymatic activity of complex II in the mitochondrial respiratory chain and activates the hypoxia pathway. Am. J. Hum. Genet. 2001, 69:1186-1197.
23. Gimenez-Roqueplo A.P., Favier J., Rustin P., Rieubland C., Crespin M., Nau V., Khau Van Kien P., Corvol P., Plouin P.F., Jeunemaitre X. Mutations in the SDHB gene are associated with extra-adrenal and/or malignant phaeochromocytomas. Cancer Res. 2003, 63:5615-5621. COMETE Network.
24. Gu H., Smith Z.D., Bock C., Boyle P., Gnirke A., Meissner A. Preparation of reduced representation bisulfite sequencing libraries for genome-scale DNA methylation profiling. Nat. Protoc. 2011, 6:468-481.
25. Hanahan D., Weinberg R.A. Hallmarks of cancer: the next generation. Cell 2011, 144:646-674.
26. Hinoue T., Weisenberger D.J., Lange C.P., Shen H., Byun H.M., Van Den Berg D., Malik S., Pan F., Noushmehr H., van Dijk C.M., et al. Genome-scale analysis of aberrant DNA methylation in colorectal cancer. Genome Res. 2012, 22:271-282.
27. Houseman E.A., Christensen B.C., Yeh R.F., Marsit C.J., Karagas M.R., Wrensch M., Nelson H.H., Wiemels J., Zheng S., Wiencke J.K., Kelsey K.T. Model-based clustering of DNA methylation array data: a recursive-partitioning algorithm for high-dimensional data arising as a mixture of beta distributions. BMC Bioinformatics 2008, 9:365.
28. Janeway K.A., Kim S.Y., Lodish M., Nosé V., Rustin P., Gaal J., Dahia P.L., Liegl B., Ball E.R., Raygada M., et al. Defects in succinate dehydrogenase in gastrointestinal stromal tumors lacking KIT and PDGFRA mutations. Proc. Natl. Acad. Sci. USA 2011, 108:314-318. NIH Pediatric and Wild-Type GIST Clinic.
29. Jones P.A., Baylin S.B. The epigenomics of cancer. Cell 2007, 128:683-692.
30. Kolski-Andreaco A., Cai H., Currle D.S., Chandy K.G., Chow R.H. Mouse adrenal chromaffin cell isolation. J. Vis. Exp. 2007, 2007 Jan 5:129.
31. Krueger F., Andrews S.R. Bismark: a flexible aligner and methylation caller for Bisulfite-Seq applications. Bioinformatics 2011, 27:1571-1572.
32. Laird P.W. The power and the promise of DNA methylation markers. Nat. Rev. Cancer 2003, 3:253-266.
33. Lenders J.W., Eisenhofer G., Mannelli M., Pacak K. Phaeochromocytoma. Lancet 2005, 366:665-675.
34. Loriot C., Burnichon N., Gadessaud N., Vescovo L., Amar L., Libé R., Bertherat J., Plouin P.F., Jeunemaitre X., Gimenez-Roqueplo A.P., Favier J. Epithelial to mesenchymal transition is activated in metastatic pheochromocytomas and paragangliomas caused by SDHB gene mutations. J. Clin. Endocrinol. Metab. 2012, 97:E954-E962.
35. Meissner A., Gnirke A., Bell G.W., Ramsahoye B., Lander E.S., Jaenisch R. Reduced representation bisulfite sequencing for comparative high-resolution DNA methylation analysis. Nucleic Acids Res. 2005, 33:5868-5877.
36. Monti S., Tamayo P., Mesirov J.P., Golub T.R. Consensus clustering. A resampling-based method for class discovery and visualization of gene-expression microarray data. Mach. Learn. 2003, 52:91-118.
37. Moreno-Bueno G., Cubillo E., Sarrió D., Peinado H., Rodríguez-Pinilla S.M., Villa S., Bolós V., Jordá M., Fabra A., Portillo F., et al. Genetic profiling of epithelial cells expressing E-cadherin repressors reveals a distinct role for Snail, Slug, and E47 factors in epithelial-mesenchymal transition. Cancer Res. 2006, 66:9543-9556.
38. Neumann H.P., Bausch B., McWhinney S.R., Bender B.U., Gimm O., Franke G., Schipper J., Klisch J., Altehoefer C., Zerres K., et al. Germ-line mutations in nonsyndromic pheochromocytoma. N.Engl. J. Med. 2002, 346:1459-1466. Freiburg-Warsaw-Columbus Pheochromocytoma Study Group.
39. Noushmehr H., Weisenberger D.J., Diefes K., Phillips H.S., Pujara K., Berman B.P., Pan F., Pelloski C.E., Sulman E.P., Bhat K.P., et al. Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. Cancer Cell 2010, 17:510-522. Cancer Genome Atlas Research Network.
40. Pasini B., Stratakis C.A. SDH mutations in tumorigenesis and inherited endocrine tumours: lesson from the phaeochromocytoma-paraganglioma syndromes. J. Intern. Med. 2009, 266:19-42.
41. Pencheva N., Tran H., Buss C., Huh D., Drobnjak M., Busam K., Tavazoie S.F. Convergent multi-miRNA targeting of ApoE drives LRP1/LRP8-dependent melanoma metastasis and angiogenesis. Cell 2012, 151:1068-1082.
42. Pollard P.J., Brière J.J., Alam N.A., Barwell J., Barclay E., Wortham N.C., Hunt T., Mitchell M., Olpin S., Moat S.J., et al. Accumulation of Krebs cycle intermediates and over-expression of HIF1alpha in tumours which result from germline FH and SDH mutations. Hum. Mol. Genet. 2005, 14:2231-2239.
43. Ricketts C., Woodward E.R., Killick P., Morris M.R., Astuti D., Latif F., Maher E.R. Germline SDHB mutations and familial renal cell carcinoma. J. Natl. Cancer Inst. 2008, 100:1260-1262.
44. Rodríguez-Paredes M., Esteller M. Cancer epigenetics reaches mainstream oncology. Nat. Med. 2011, 17:330-339.
45. Rutter J., Winge D.R., Schiffman J.D. Succinate dehydrogenase - assembly, regulation and role in human disease. Mitochondrion 2010, 10:393-401.
46. Selak M.A., Armour S.M., MacKenzie E.D., Boulahbel H., Watson D.G., Mansfield K.D., Pan Y., Simon M.C., Thompson C.B., Gottlieb E. Succinate links TCA cycle dysfunction to oncogenesis by inhibiting HIF-alpha prolyl hydroxylase. Cancer Cell 2005, 7:77-85.
47. Takai D., Jones P.A. Comprehensive analysis of CpG islands in human chromosomes 21 and 22. Proc. Natl. Acad. Sci. USA 2002, 99:3740-3745.
48. Tomlinson I.P., Alam N.A., Rowan A.J., Barclay E., Jaeger E.E., Kelsell D., Leigh I., Gorman P., Lamlum H., Rahman S., et al. Germline mutations in FH predispose to dominantly inherited uterine fibroids, skin leiomyomata and papillary renal cell cancer. Nat. Genet. 2002, 30:406-410. Multiple Leiomyoma Consortium.
49. Toyota M., Ahuja N., Ohe-Toyota M., Herman J.G., Baylin S.B., Issa J.P. CpG island methylator phenotype in colorectal cancer. Proc. Natl. Acad. Sci. USA 1999, 96:8681-8686.
50. Tsai H.C., Li H., Van Neste L., Cai Y., Robert C., Rassool F.V., Shin J.J., Harbom K.M., Beaty R., Pappou E., et al. Transient low doses of DNA-demethylating agents exert durable antitumor effects on hematological and epithelial tumor cells. Cancer Cell 2012, 21:430-446.
51. van Nederveen F.H., Gaal J., Favier J., Korpershoek E., Oldenburg R.A., de Bruyn E.M., Sleddens H.F., Derkx P., Rivière J., Dannenberg H., et al. An immunohistochemical procedure to detect patients with paraganglioma and phaeochromocytoma with germline SDHB, SDHC, or SDHD gene mutations: a retrospective and prospective analysis. Lancet Oncol. 2009, 10:764-771.
52. Smallwood S.A., Kelsey G. Genome-wide analysis of DNA methylation in low cell numbers by reduced representation bisulfite sequencing. Methods Mol. Biol. 2012, 925:187-197.
53. Ward P.S., Thompson C.B. Metabolic reprogramming: a cancer hallmark even warburg did not anticipate. Cancer Cell 2012, 21:297-308.
54. Widschwendter M., Fiegl H., Egle D., Mueller-Holzner E., Spizzo G., Marth C., Weisenberger D.J., Campan M., Young J., Jacobs I., Laird P.W. Epigenetic stem cell signature in cancer. Nat. Genet. 2007, 39:157-158.
55. Xiao M., Yang H., Xu W., Ma S., Lin H., Zhu H., Liu L., Liu Y., Yang C., Xu Y., et al. Inhibition of α-KG-dependent histone and DNA demethylases by fumarate and succinate that are accumulated in mutations of FH and SDH tumor suppressors. Genes Dev. 2012, 26:1326-1338.
56. Xu W., Yang H., Liu Y., Yang Y., Wang P., Kim S.H., Ito S., Yang C., Wang P., Xiao M.T., et al. Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of α-ketoglutarate-dependent dioxygenases. Cancer Cell 2011, 19:17-30.
57. Young R.M., Simon M.C. Untuning the tumor metabolic machine: HIF-α: pro- and antitumorigenic?. Nat. Med. 2012, 18:1024-1025.